Chapter 2 — The upstream lever: mitochondrial integrity before substrate

Pouring NAD+ into broken mitochondria is wasted spend.

Every gram of NMN you take, every NAD+ IV you book, every methylene-blue capsule — all of it lands on the same terminal hardware: the electron transport chain studded along your inner mitochondrial membrane. If that membrane is structurally compromised, substrate doesn't rescue it. It feeds it. The peptide-research corpus is explicit on this: damaged mitochondria don't just fail to produce ATP — they actively amplify the damage signal by leaking reactive oxygen species, releasing cardiolipin and mtDNA as damage-associated molecular patterns (mtDAMPs), and triggering inflammasome activation downstream. You can't substrate-supplement your way out of a structural problem. You have to fix the membrane first. That is the upstream lever this chapter pulls.

What's actually happening at the membrane

The inner mitochondrial membrane folds into cristae — accordion-pleated invaginations that house the electron transport chain. The structural integrity of those folds depends on a single phospholipid: cardiolipin. Cardiolipin has a unique conical shape that aggregates into non-bilayer structures and causes the inner membrane to buckle and form cristae curvature. Deficiency or oxidation of cardiolipin results in absent or disorganized cristae, and the entire respiratory machinery becomes inefficient. The substrate documents this directly: "Cardiolipin has a unique conical shape that aggregates into non-bilayer structures and causes the IMM to buckle and form cristae curvatures. Deficiency in cardiolipin results in absent or disorganized cristae structure."

When cardiolipin oxidizes — a default consequence of aging, chronic inflammation, gut dysbiosis-driven LPS exposure, and metabolic stress — three things happen in sequence:

1. Electron transport chain efficiency drops. Electrons leak out of complex I and complex III instead of being shuttled cleanly to oxygen. Each leaked electron generates a superoxide radical. ATP output falls, reactive oxygen species rise.
2. The ROS damages the very cardiolipin holding the membrane together. This is the self-amplifying feedback loop the corpus repeatedly flags: mitochondrial dysfunction "acts both as an initiating insult and as a consequence of tubular cell injury, creating a self-amplifying feedback loop that accelerates" the underlying pathology.
3. Damaged mitochondria release cardiolipin and mtDNA into the cytoplasm, where they're recognized as DAMPs and activate the NLRP3 inflammasome. Now you have systemic inflammation driven by the very organelles supposed to be powering the cell. Practitioner consensus on this loop is unanimous: in gut dysbiosis (estimated to affect ~70% of Americans), LPS crosses the gut barrier, activates systemic inflammation, and damages mitochondria — which then leak DAMPs and amplify the inflammation further.

If you pour NAD+ precursors into this system, you're handing fuel to a leaky engine. More substrate means more electrons through a compromised chain, which means more ROS, which means faster cardiolipin destruction. This is the corpus position. NAD+ comes later in the path for a reason — Chapter 3 substrate work only pays off after the membrane is stabilized, biogenesis is signaled, and damaged mitochondria are cleared.

The three upstream operations

Three operations have to run, in this order, before NAD+ substrate becomes worth the spend:

Operation 1 — Stabilize the existing membrane. SS-31 / elamipretide binds selectively to cardiolipin in the inner mitochondrial membrane. The peptide-bilayer interaction produces what the substrate calls a "controlled down-tuning of the negative charge density of the CL-rich bilayers," which preserves cristae geometry and restores electron transport efficiency without disrupting normal proton flow. This is the only intervention in the peptide stable that directly protects the structural lipid holding the respiratory chain together.

Operation 2 — Signal biogenesis of new, undamaged mitochondria. This runs through PGC-1α, the master regulator the corpus repeatedly names as the gatekeeper of mitochondrial biogenesis. MOTS-c is the only known peptide encoded directly in mitochondrial DNA, and the corpus frames it as "the master signal that tells your cells to produce more energy, burn more fat, and build" new mitochondria. Practitioner observation tracks with this: MOTS-c administration correlates with restored insulin sensitivity and improved muscle bioenergetics across multiple cohorts cited in the substrate.

Operation 3 — Clear the damaged ones via mitophagy. This is the AMPK arm. The corpus is explicit that AMPK and mTOR function as a seesaw — when AMPK is high, mTOR is low; when mTOR is high, AMPK is low — and you want to cycle that seesaw regularly through the week. AMPK activation (via fasting windows, fasted training) triggers autophagy generally and mitophagy specifically: damaged mitochondria are tagged via the PINK1/Parkin pathway and degraded before they can keep leaking ROS and DAMPs.

The peptide stack handles operations 1 and 2. Lifestyle handles operation 3.

Phase 0 stack: mitochondrial integrity (Weeks 1–4)

Run this before the NAD+ substrate layer that begins in Chapter 3. The goal of these four weeks is structural — fix the engine before adding fuel.

What you should feel

The substrate is thin on week-by-week subjective milestones for Phase 0 specifically, so set expectations conservatively. The corpus does document the following:

• Weeks 1–2: subtle. Cardiolipin remodeling is a structural process, not a stimulant effect. If you feel a stimulant kick, it's not from this stack.
• Weeks 2–3: the corpus notes that some users feel transiently more tired on MOTS-c — this is a known practitioner-flagged effect tied to mitochondrial remodeling load. The substrate frames it as expected, not pathological.
• Weeks 3–4: practitioner consensus describes improved exercise recovery, less post-training inflammation, and a quieter baseline. The corpus connects this to reduced ROS leak as cristae geometry normalizes.

What's NOT happening yet

• You're not getting the NAD+ uplift yet. That's Chapter 3. Trying to feel it during Phase 0 is the wrong test.
• You're not getting peak energy output. Biogenesis takes 4–6 weeks to express as measurable mitochondrial density. The corpus is explicit that PGC-1α activation triggers a response in which the body builds "more, also bigger mitochondria" — but this is a structural rebuild, not a same-week stimulant.
• You're not getting fat-loss effects from MOTS-c yet. Those track to operation 2 maturing, which compounds across weeks 4–10.
• Inflammation markers won't all drop in week one. The mtDAMP→NLRP3 loop takes weeks to quiet as damaged mitochondria are progressively cleared via mitophagy.

If you check labs at week 2 and nothing looks dramatic, that is expected. Phase 0 is the foundation, not the visible win.

The corpus describes a structural rebuild, not a stimulant. Run the four weeks. Track recovery, sleep, and resting heart-rate variability. Then layer the substrate.